The Resource Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease : identification of future research needs from Comparative effectiveness review no. 18, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Gillian D. Sanders ... [et al.], (electronic resource)

Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease : identification of future research needs from Comparative effectiveness review no. 18, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Gillian D. Sanders ... [et al.], (electronic resource)

Label
Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease : identification of future research needs from Comparative effectiveness review no. 18
Title
Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease
Title remainder
identification of future research needs from Comparative effectiveness review no. 18
Statement of responsibility
prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Gillian D. Sanders ... [et al.]
Contributor
Subject
Language
eng
Summary
A comparative effectiveness review (CER) published by the University of Connecticut Evidence-based Practice Center (EPC) in 2009 found strong evidence that ACE inhibitors reduced total mortality and nonfatal myocardial infarction (MI) in comparison to placebo among adults with stable IHD and preserved ventricular function, but increased the risk for syncope and cough. There was low to moderate evidence that ARBs reduced a composite of cardiovascular endpoints compared to placebo, and these agents were well-tolerated. The one available study directly comparing the impact of ACE inhibitors and ARBs on cardiovascular outcomes in patients with IHD revealed no significant difference between the classes in the rate of cardiovascular outcomes, but demonstrated higher rates of cough and angioedema among patients treated with ACE inhibitors, and higher rates of hypotensive symptoms among patients treated with ARBs. A list of research gaps is a common component of CERs and is an important step in outlining a future research agenda; however, such lists do not always clearly suggest how future research should be prioritized, or which projects are in fact feasible. In this pilot project, we sought to expand on the work done by the University of Connecticut EPC to identify and prioritize gaps in the evidence supporting the comparative effectiveness of ACE inhibitor and ARB therapy in patients with IHD. The prioritization process we used combined a review of recently published and ongoing studies, engagement of nine stakeholders, and participation of these stakeholders in both qualitative and quantitative exercises of research needs prioritization
Member of
Cataloging source
DNLM
http://bibfra.me/vocab/lite/collectionName
Comparative effectiveness of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease
Funding information
Contract No. 290-2007-10066-I
NLM call number
WG 300
http://library.link/vocab/relatedWorkOrContributorName
  • Sanders, Gillian D
  • Effective Health Care Program (U.S.)
  • United States
  • Duke University Evidence-based Practice Center
Series statement
  • Future research needs paper
  • AHRQ publication
Series volume
  • no. 8
  • no. 11-EHC005-EF
http://library.link/vocab/subjectName
  • Myocardial Ischemia
  • Angiotensin-Converting Enzyme Inhibitors
  • Angiotensin Receptor Antagonists
  • Research Design
  • Forecasting
  • Pilot Projects
  • United States
  • United States
Label
Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease : identification of future research needs from Comparative effectiveness review no. 18, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Gillian D. Sanders ... [et al.], (electronic resource)
Instantiates
Publication
Note
  • Title from PDF t.p
  • "November 2010."
Bibliography note
Includes bibliographical references
Control code
OCM1bookssj0000994184
Dimensions
unknown
Specific material designation
remote
System control number
(WaSeSS)bookssj0000994184
System details
Mode of access: Internet
Label
Future research needs for angiotensin converting enzyme inhibitors or angiotensin II receptor blockers added to standard medical therapy for treating stable ischemic heart disease : identification of future research needs from Comparative effectiveness review no. 18, prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Gillian D. Sanders ... [et al.], (electronic resource)
Publication
Note
  • Title from PDF t.p
  • "November 2010."
Bibliography note
Includes bibliographical references
Control code
OCM1bookssj0000994184
Dimensions
unknown
Specific material designation
remote
System control number
(WaSeSS)bookssj0000994184
System details
Mode of access: Internet

Library Locations

    • Thomas Jefferson LibraryBorrow it
      1 University Blvd, St. Louis, MO, 63121, US
      38.710138 -90.311107
Processing Feedback ...